Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China

Background and purpose: The latest RATIONALE-302 trial (NCT03430843) showed that tislelizumab therapy significantly improved overall survival benefits for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) compared with traditional chemotherapy. This study aimed to compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Fenghao, He, Zixuan, Su, Hang, Wang, Lin, Han, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708733/
https://www.ncbi.nlm.nih.gov/pubmed/36467065
http://dx.doi.org/10.3389/fphar.2022.961347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708733/
https://www.ncbi.nlm.nih.gov/pubmed/36467065
http://dx.doi.org/10.3389/fphar.2022.961347

Ejemplares similares